It’s not an AIDS vaccine but it may be the closest thing to one so far. A long-acting antiretroviral drug given as an injection every 2 months powerfully protected uninfected people from HIV in a large-scale study that was disrupted by the COVID-19 pandemic.
Men living with HIV (MLHIV) have a high burden of human papillomavirus (HPV)-related cancer. Understanding serological dynamics of HPV in men can guide decisions on introducing HPV vaccination and monitoring impact.
With the rapid spread of COVID-19 across Africa, m2m President & CEO, Frank Beadle de Palomo, looks at how countries and organisations are harnessing lessons learned from the HIV/AIDS response to mitigate the impact of this new pandemic.
The COVID-19 pandemic represents an unprecedented global emergency that has now infected more than 3 million people worldwide and is already the most lethal new pandemic since the emergence of AIDS nearly 40 years ago.
The HIV pandemic provides lessons for the response to the novel coronavirus disease 2019 (COVID-19) pandemic: no vaccine is available for either and there are no licensed pharmaceuticals for COVID-19, just as there was not for HIV infection in the early years.
South Africa has spent the last two decades fighting against its deadly HIV and TB epidemics, and many of its HIV researchers are now mustering their expertise to battle the Covid-19 pandemic.The scientific community has “galvanized” to investigate the novel coronavirus and the disease it causes,